Comparing the Ceftolozane–Tazobactam & Ceftazidime–Avibactam Combinations in Treating Multidrug Resistant Pseudomonas aeruginosa
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on June 23rd, 2025
|
Pseudomonas aeruginosa is a prevalent bacterial pathogen, and infections caused by multidrug-resistant strains pose a significant clinical threat. While the antibiotic combinations ceftolozane–tazobactam and ceftazidime–avibactam have shown efficacy against resistant strains, limited data exist comparing their performance across different clinical scenarios. To address this gap and support the refinement of treatment guidelines, a study funded by Merck was conducted to evaluate their relative effectiveness.
The trial took place in the United States and involved 420 hospitalized patients with confirmed invasive infections due to multidrug-resistant P. aeruginosa, defined as resistance to at least three antibiotic classes. The majority of cases (80%) were due to pneumonia, while the remaining participants were hospitalized for bacteremia. Specific pathogen resistance profiles were not disclosed in the study report.
Participants were randomly assigned to receive either ceftolozane–tazobactam or ceftazidime–avibactam. Administration routes were determined by clinicians, with 10% of patients receiving inhaled therapy and 15% receiving intravenous antibiotics. Both treatment regimens pair a cephalosporin (ceftolozane or ceftazidime) with a β-lactamase inhibitor (tazobactam or avibactam), aiming to disrupt bacterial cell wall synthesis while neutralizing resistance mechanisms.
After approximately nine days of treatment, the ceftolozane–tazobactam group demonstrated superior clinical efficacy in treating pneumonia caused by multidrug-resistant P. aeruginosa, while no significant difference in outcomes was observed between the two regimens in patients with bacteremia. Additionally, rates of mortality after discharge and disease recurrence were similar between the groups.
The trial took place in the United States and involved 420 hospitalized patients with confirmed invasive infections due to multidrug-resistant P. aeruginosa, defined as resistance to at least three antibiotic classes. The majority of cases (80%) were due to pneumonia, while the remaining participants were hospitalized for bacteremia. Specific pathogen resistance profiles were not disclosed in the study report.
Participants were randomly assigned to receive either ceftolozane–tazobactam or ceftazidime–avibactam. Administration routes were determined by clinicians, with 10% of patients receiving inhaled therapy and 15% receiving intravenous antibiotics. Both treatment regimens pair a cephalosporin (ceftolozane or ceftazidime) with a β-lactamase inhibitor (tazobactam or avibactam), aiming to disrupt bacterial cell wall synthesis while neutralizing resistance mechanisms.
After approximately nine days of treatment, the ceftolozane–tazobactam group demonstrated superior clinical efficacy in treating pneumonia caused by multidrug-resistant P. aeruginosa, while no significant difference in outcomes was observed between the two regimens in patients with bacteremia. Additionally, rates of mortality after discharge and disease recurrence were similar between the groups.